Timothy J. Hobday, MD

Timothy J. Hobday, MD, is associate professor of oncology at the Mayo Clinic College of Medicine and Science in Rochester, MN. Mayo Clinic in Rochester has been ranked as a top institution in the United States by the U.S. News & World Report and as the world’s best hospital by Newsweek.

Dr Hobday received his undergraduate degree from Carleton College in Northfield, MN. After graduating from the Mayo Medical School, he completed his internal medicine residency and hematology/oncology fellowship at the Mayo Graduate School of Medicine. He joined the faculty of the Department of Oncology at Mayo Clinic in Rochester, with a research and career focus on neuroendocrine tumors (NETs). He also has been active in research and leadership in breast cancer and graduate medical education. He is the education chair for the Division of Medical Oncology and the program director of the Hematology/Oncology Fellowship at Mayo Clinic in Rochester.

Dr Hobday has authored or coauthored more than 100 publications and is an active member of numerous professional medical societies. He has written and served as principal investigator for several clinical trials of novel therapies for NETs, including a newly approved, national, multicenter, randomized trial of peptide receptor radionuclide therapy vs chemotherapy in pancreatic NETs. He has also been coinvestigator for many practice-changing international phase 2 and 3 trials in NETs. He has been a member of the National Cancer Institute Neuroendocrine Tumor Clinical Trial Task Force for several years. His major professional interests are focused on the study and management of NETS, as well as the training of the next generation of hematologists/oncologists.